Kristin N Anderson, MD
Medical Oncology · Greenbrae
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Office
- 1
- Since medical school
- 17 years
- University of Minnesota Medical School, 2009
Offices
1 location · Marin Cancer Care, Inc. · 13 clinicians in this group
Hospitals listed: Marinhealth Medical Center · Novato Community Hospital · Sonoma Valley Hospital. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Anderson’s office at (415) 925-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Marinhealth Medical CenterGreenbrae, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of MarinHealthPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.66 (3.59 to 7.73) · 1,505 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.177, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025
- Novato Community HospitalNovato, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Sonoma Valley HospitalSonoma, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency departmentPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 2 of 5 starsNo measure marked better or worse than the national rate
See every measure and the patient survey for Marinhealth Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 3 better, 8 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.66 (3.59 to 7.73) · 1,505 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.177 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.85 (0 to 1.83) · 1,056 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.04 (0.72 to 1.36) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.34 (112.58 to 222.09) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 47 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 119 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.6 · 257 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 428 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.4 · 477 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 197 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,827 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.38) · 6,990 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.41) · 6,838 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 664 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.86 (1.4 to 4.33) · 1,436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.38 (3.68 to 17.08) · 705 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.38 (0.72 to 8.04) · 672 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.18 to 3.15) · 300 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.56 (0 to 1.25) · 5,550 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 76 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.396 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 275 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 427 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -20.3 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 3.3 · 494 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.9 · 499 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 435 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.6 to 8.4) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.2 (7.8 to 16) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.6 · 84 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 111 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (10.3 to 16.5) · 2,119 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 670 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,233 patients answered, 19% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Novato Community Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.06) · 213 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.4 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 25 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10 · 111 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.1 · 140 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.3 · 42 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 627 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,872 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 1,796 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.92 (0.5 to 5.33) · 505 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.36) · 317 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.2 (0.51 to 3.88) · 495 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.93 (0 to 17.29) · 323 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.88 (0.69 to 9.07) · 311 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.22 to 3.27) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.41 (0 to 1.49) · 1,320 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 143 cases | None | Apr 2023 – Mar 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 108 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.9 · 121 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.1 · 150 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 118 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 27 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.5 to 16.5) · 930 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 184 cases | No different | Jan 2024 – Dec 2024 |
What patients said (334 patients answered, 30% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 84% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sonoma Valley Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 6 the same, 0 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.11 (0.63 to 1.6) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 37 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.6 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 35 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 5.6 · 345 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.44) · 713 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.05 to 0.48) · 660 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.36 (0.77 to 5.94) · 101 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.65 (0 to 3.38) · 27 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.31 (0.58 to 4.03) · 100 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.86 (0 to 18.76) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (0.84 to 9.45) · 27 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.12 (0 to 2.33) · 540 cases | No different | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.651 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.1 · 60 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 15.5 · 47 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18 · 105 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 47 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.6 (10.2 to 17.9) · 486 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.3) · 83 cases | No different | Jan 2024 – Dec 2024 |
What patients said (164 patients answered, 31% of those asked)
| Cleanliness | 4 |
| Nurse communication | 5 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 85% |
| Doctors "always" communicated well | 88% |
| Staff "always" explained | 65% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 84% |
| Doctors "always" listened carefully | 88% |
| Doctors "always" treated them with courtesy and respect | 92% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 81% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 91% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 53% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$3,013,066
Medicare paid this office $3,013,066 for 388 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 83 | $44,489 | $154 |
| Return visit (30+ min) | 228 | $44,385 | $103 |
| Administration of chemotherapy into vein, 1 hour or less | 35 | $38,883 | $126 |
| Short return visit (20+ min) | 100 | $7,732 | $72 |
| Administration of additional new drug or substance into vein, 1 hour or less | 18 | $6,844 | $62 |
See all 18 services
| Long return visit (40+ min) | 83 | $44,489 | $154 |
| Return visit (30+ min) | 228 | $44,385 | $103 |
| Administration of chemotherapy into vein, 1 hour or less | 35 | $38,883 | $126 |
| Short return visit (20+ min) | 100 | $7,732 | $72 |
| Administration of additional new drug or substance into vein, 1 hour or less | 18 | $6,844 | $62 |
| New patient visit (60+ min) | 36 | $6,560 | $182 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 18 | $6,290 | $0 |
| Injection of additional new drug or substance into vein | 30 | $4,216 | $14 |
| Administration of chemotherapy into vein, each additional hour | 22 | $3,628 | $25 |
| New patient visit (30+ min) | 39 | $3,580 | $92 |
| Injection of drug or substance under skin or into muscle | 40 | $3,118 | $12 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,364 | $139 |
| Injection of drug or substance into vein | 26 | $1,874 | $35 |
| Injection, carboplatin, 50 mg | 11 | $1,235 | None |
| Infusion, normal saline solution , 1000 cc | 51 | $922 | None |
| Injection, palonosetron hcl, 25 mcg | 20 | $719 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 24 | $222 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 18 | $40 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Biopsy and aspiration of bone marrow sample for diagnosis | 14 | – | – | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
388 Original Medicare patients in 2024. Average age 77 · Under 65 3% · 85 and older 15% · Women 64% · Also on Medicaid 11% · Health risk score 1.59. At or below the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: High blood pressure 62% · Cancer 48% · Coronary heart disease 24% · Chronic kidney disease 24% · Depression 21% · Atrial fibrillation 19% · Diabetes 16% · Heart failure 14% · Stroke 12% · COPD 11% · Dementia 4%.
The office billed $9,254,177, Medicare allowed $3,794,258 and paid $3,013,066; for 155,814 services of 87 kinds; $2,819,813 of it was for drugs given in the office and $193,253 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 388 | 155,814 | 77 | 1.59 | $9,254,177 | $3,013,066 |
| 2023 | 393 | 133,919 | 77 | 1.65 | $7,303,252 | $2,322,823 |
| 2022 | 438 | 146,003 | 76 | 1.65 | $8,018,602 | $2,571,750 |
| 2021 | 409 | 102,284 | 76 | 1.71 | $5,880,215 | $1,859,916 |
| 2020 | 358 | 103,957 | 76 | 1.85 | $5,125,142 | $1,641,744 |
| 2019 | 382 | 75,740 | 76 | 1.73 | $3,672,777 | $1,152,566 |
| 2018 | 359 | 60,222 | 76 | 1.86 | $3,057,697 | $953,265 |
| 2017 | 391 | 70,078 | 76 | 1.87 | $3,553,696 | $1,082,729 |
| 2016 | 453 | 83,108 | 76 | 2.00 | $2,683,098 | $815,471 |
| 2015 | 113 | 9,235 | 76 | 1.75 | $384,798 | $122,357 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 20 services
| Return visit (30+ min) | 256 | $60,543 | $112 |
| Administration of chemotherapy into vein, 1 hour or less | 38 | $31,167 | $134 |
| Long return visit (40+ min) | 82 | $30,802 | $167 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 11 | $28,990 | None |
| Short return visit (20+ min) | 88 | $7,912 | $74 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 13 | $7,903 | $0 |
| Administration of chemotherapy into vein, each additional hour | 23 | $4,853 | $28 |
| Injection of additional new drug or substance into vein | 31 | $4,608 | $16 |
| New patient visit (60+ min) | 22 | $4,478 | $204 |
| Injection of drug or substance under skin or into muscle | 34 | $4,258 | $13 |
| Administration of additional new drug or substance into vein, 1 hour or less | 15 | $4,254 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,004 | $148 |
| New patient visit (45+ min) | 23 | $3,559 | $155 |
| Injection of drug or substance into vein | 28 | $2,358 | $37 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $2,218 | $106 |
| New patient visit (30+ min) | 24 | $2,061 | $86 |
| Injection, palonosetron hcl, 25 mcg | 14 | $392 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 24 | $134 | None |
| Infusion, normal saline solution , 1000 cc | 14 | $104 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 21 | $59 | None |
2022: 26 services
| Return visit (30+ min) | 241 | $60,216 | $120 |
| Administration of chemotherapy into vein, 1 hour or less | 46 | $52,271 | $144 |
| Short return visit (20+ min) | 238 | $28,879 | $75 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 19 | $22,001 | $1 |
| Administration of chemotherapy into vein, each additional hour | 33 | $10,705 | $30 |
| Long return visit (40+ min) | 33 | $8,834 | $170 |
| Injection of additional new drug or substance into vein | 39 | $8,619 | $16 |
| Administration of additional new drug or substance into vein, 1 hour or less | 21 | $7,396 | $70 |
| New patient visit (60+ min) | 31 | $6,264 | $202 |
| Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise | 13 | $4,720 | $197 |
| Injection of drug or substance under skin or into muscle | 41 | $3,376 | $14 |
| Injection of drug or substance into vein | 33 | $3,341 | $38 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,207 | $178 |
| New patient visit (45+ min) | 20 | $2,842 | $142 |
| New patient visit (30+ min) | 24 | $2,182 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $1,941 | $92 |
| Infusion into a vein for hydration, 31-60 minutes | 18 | $1,789 | $36 |
| Short return visit | 60 | $1,705 | $27 |
| Injection, zoledronic acid, 1 mg | 17 | $820 | None |
| Injection, palonosetron hcl, 25 mcg | 25 | $817 | None |
| Injection, carboplatin, 50 mg | 12 | $761 | None |
| Infusion, normal saline solution , 1000 cc | 47 | $569 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 36 | $268 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 17 | $80 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 16 | $67 | None |
| Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise | 13 | $0 | $0 |
2021: 23 services
| Injection, pembrolizumab, 1 mg | 11 | $312,871 | None |
| Short return visit (20+ min) | 283 | $48,342 | $74 |
| Administration of chemotherapy into vein, 1 hour or less | 51 | $31,201 | $148 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 17 | $20,891 | $1 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 12 | $20,012 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 41 | $7,298 | $178 |
| Return visit (30+ min) | 36 | $5,370 | $107 |
| Administration of additional new drug or substance into vein, 1 hour or less | 17 | $4,927 | $74 |
| New patient visit (60+ min) | 24 | $4,626 | $193 |
| Short return visit | 84 | $4,351 | $34 |
| Injection of drug or substance into vein | 39 | $3,785 | $40 |
| Injection of drug or substance under skin or into muscle | 41 | $3,378 | $13 |
| New patient visit (45+ min) | 26 | $3,310 | $127 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $3,048 | $92 |
| Injection of additional new drug or substance into vein | 38 | $2,298 | $17 |
| New patient visit (30+ min) | 34 | $1,954 | $57 |
| Injection, zoledronic acid, 1 mg | 27 | $1,804 | None |
| Administration of chemotherapy into vein, each additional hour | 14 | $1,445 | $31 |
| Infusion, normal saline solution , 1000 cc | 93 | $1,434 | None |
| Injection, palonosetron hcl, 25 mcg | 16 | $662 | None |
| Injection, carboplatin, 50 mg | 11 | $362 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 26 | $195 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 13 | $22 | None |
2020: 22 services
| Short return visit (20+ min) | 283 | $40,020 | $55 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 17 | $39,830 | None |
| Administration of chemotherapy into vein, 1 hour or less | 50 | $29,548 | $141 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 12 | $20,897 | $1 |
| Return visit (30+ min) | 36 | $5,490 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $5,133 | $183 |
| Administration of additional new drug or substance into vein, 1 hour or less | 15 | $4,832 | $70 |
| Injection of drug or substance under skin or into muscle | 48 | $3,964 | $14 |
| Injection of drug or substance into vein | 35 | $3,747 | $39 |
| New patient visit (60+ min) | 18 | $2,991 | $166 |
| Administration of chemotherapy into vein, each additional hour | 22 | $2,410 | $31 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $2,368 | $95 |
| Injection of additional new drug or substance into vein | 35 | $2,160 | $16 |
| Injection, zoledronic acid, 1 mg | 25 | $1,830 | None |
| New patient visit (45+ min) | 14 | $1,648 | $118 |
| Short return visit | 42 | $1,583 | $30 |
| Infusion, normal saline solution , 1000 cc | 92 | $1,324 | None |
| Injection, palonosetron hcl, 25 mcg | 18 | $1,006 | None |
| New patient visit (30+ min) | 14 | $959 | $68 |
| Injection, dexamethasone sodium phosphate, 1 mg | 23 | $78 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 13 | $23 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 13 | $20 | None |
2019: 27 services
| Injection, pegfilgrastim, 6 mg | 14 | $141,543 | None |
| Short return visit (20+ min) | 285 | $45,109 | $62 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 15 | $28,470 | None |
| Administration of chemotherapy into vein, 1 hour or less | 53 | $24,880 | $138 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 11 | $14,140 | $1 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 43 | $7,843 | $178 |
| Injection, palonosetron hcl, 25 mcg | 35 | $5,970 | None |
| New patient visit (60+ min) | 33 | $5,890 | $178 |
| Administration of additional new drug or substance into vein, 1 hour or less | 24 | $4,990 | $68 |
| Return visit (30+ min) | 36 | $4,580 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $4,214 | $92 |
| Injection of drug or substance under skin or into muscle | 38 | $3,110 | $15 |
| Injection of additional new drug or substance into vein | 46 | $2,970 | $16 |
| New patient visit (30+ min) | 32 | $2,907 | $91 |
| Administration of chemotherapy into vein, each additional hour | 27 | $2,845 | $30 |
| Injection of drug or substance into vein | 31 | $2,486 | $36 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 14 | $2,268 | $162 |
| Administration of additional new drug or substance into vein using push technique | 14 | $1,761 | $59 |
| New patient visit (45+ min) | 11 | $1,501 | $136 |
| Injection, zoledronic acid, 1 mg | 23 | $1,450 | None |
| Infusion, normal saline solution , 1000 cc | 87 | $1,121 | None |
| Short return visit | 22 | $896 | $34 |
| Injection, carboplatin, 50 mg | 11 | $334 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $244 | $22 |
| Injection, dexamethasone sodium phosphate, 1 mg | 40 | $168 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 13 | $18 | None |
| Unclassified drugs | 11 | $14 | None |
2018: 22 services
| Short return visit (20+ min) | 277 | $43,508 | $62 |
| Administration of chemotherapy into vein, 1 hour or less | 50 | $22,323 | $134 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 15 | $21,050 | $1 |
| Injection, palonosetron hcl, 25 mcg | 20 | $5,264 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $4,067 | $177 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $4,004 | $91 |
| New patient visit (60+ min) | 20 | $3,355 | $168 |
| New patient visit (30+ min) | 38 | $3,250 | $86 |
| Injection of drug or substance into vein | 26 | $2,744 | $46 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 26 | $2,619 | $64 |
| Injection of drug or substance under skin or into muscle | 24 | $2,279 | $18 |
| Return visit (30+ min) | 18 | $2,161 | $98 |
| Administration of additional new drug or substance into vein, 1 hour or less | 18 | $2,091 | $67 |
| Administration of chemotherapy into vein, each additional hour | 19 | $2,079 | $30 |
| Injection, zoledronic acid, 1 mg | 20 | $1,805 | None |
| Short return visit | 37 | $1,737 | $36 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 27 | $1,438 | $30 |
| Infusion, normal saline solution , 1000 cc | 86 | $980 | None |
| Injection of additional new drug or substance into vein | 20 | $878 | $18 |
| Injection, carboplatin, 50 mg | 11 | $299 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 28 | $70 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 13 | $18 | None |
2017: 26 services
| Injection, rituximab, 100 mg | 13 | $130,104 | None |
| Short return visit (20+ min) | 287 | $44,564 | $61 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 15 | $37,663 | None |
| Administration of chemotherapy into vein, 1 hour or less | 52 | $29,104 | $134 |
| New patient visit (60+ min) | 78 | $13,468 | $173 |
| Return visit (30+ min) | 80 | $10,935 | $91 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 15 | $10,763 | $1 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 45 | $8,239 | $175 |
| Injection, palonosetron hcl, 25 mcg | 24 | $7,920 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 40 | $7,682 | $90 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 39 | $6,893 | $65 |
| Injection of drug or substance under skin or into muscle | 40 | $4,755 | $24 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 47 | $4,164 | $30 |
| Administration of additional new drug or substance into vein, 1 hour or less | 25 | $3,246 | $64 |
| Administration of chemotherapy into vein, each additional hour | 31 | $3,081 | $27 |
| Injection, zoledronic acid, 1 mg | 22 | $2,006 | None |
| Aspiration of bone marrow sample for diagnosis | 11 | $1,768 | $161 |
| Biopsy of bone marrow | 15 | $1,604 | $107 |
| Infusion, normal saline solution , 1000 cc | 83 | $990 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 20 | $917 | $20 |
| Injection, carboplatin, 50 mg | 11 | $783 | None |
| Short return visit | 20 | $764 | $38 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 17 | $458 | $17 |
| Injection, dexamethasone sodium phosphate, 1 mg | 39 | $139 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 20 | $48 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 18 | $21 | None |
2016: 27 services
| Injection, rituximab, 100 mg | 12 | $94,664 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 13 | $90,589 | None |
| Short return visit (20+ min) | 277 | $44,033 | $60 |
| Administration of chemotherapy into vein, 1 hour or less | 59 | $24,730 | $131 |
| Return visit (30+ min) | 117 | $19,642 | $97 |
| New patient visit (60+ min) | 83 | $14,685 | $177 |
| Ct scan of abdomen and pelvis with contrast | 47 | $10,542 | $220 |
| Injection, palonosetron hcl, 25 mcg | 28 | $9,536 | None |
| Injection of drug or substance under skin or into muscle | 33 | $6,605 | $24 |
| Ct scan of chest with contrast | 58 | $6,205 | $107 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,953 | $175 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 54 | $5,642 | $29 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $5,215 | $90 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 21 | $3,284 | $63 |
| Administration of additional new drug or substance into vein, 1 hour or less | 24 | $3,248 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,999 | $61 |
| Long return visit (40+ min) | 13 | $1,952 | $122 |
| Administration of chemotherapy into vein, each additional hour | 20 | $1,440 | $27 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 26 | $1,413 | $20 |
| Administration of additional new drug or substance into vein using push technique | 13 | $1,342 | $61 |
| Infusion, normal saline solution , 1000 cc | 83 | $735 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $490 | $19 |
| Short return visit | 11 | $336 | $31 |
| Injection, dexamethasone sodium phosphate, 1 mg | 42 | $185 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 22 | $51 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 23 | $23 | None |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 72 | $7 | $0 |
2015: 9 services
| Short return visit (20+ min) | 63 | $5,442 | $66 |
| New patient visit (60+ min) | 25 | $4,612 | $184 |
| Administration of chemotherapy into vein, 1 hour or less | 16 | $3,761 | $134 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,291 | $176 |
| Return visit (30+ min) | 16 | $1,959 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,953 | $63 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 14 | $734 | $29 |
| Infusion, normal saline solution , 1000 cc | 22 | $102 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 11 | $25 | None |
Medicaid work
$602 in 2024
Medicaid paid $602 for 12 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 12 | $602 |
| 2024 | 12 | 1 | 12 | $602 |
| 2023 | 99 | 2 | 15 | $5,016 |
| 2022 | 158 | 2 | 23 | $5,802 |
| 2021 | 132 | 1 | 25 | $4,291 |
| 2020 | 181 | 1 | 26 | $4,229 |
| 2019 | 74 | 1 | 16 | $2,711 |
| 2018 | 30 | 1 | 15 | $1,332 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 83 | $3,747 |
| Long return visit (40+ min) | 16 | $1,270 |
2022
| Return visit (30+ min) | 72 | $2,983 |
| Short return visit (20+ min) | 86 | $2,818 |
2021
| Short return visit (20+ min) | 132 | $4,291 |
2020
| Short return visit (20+ min) | 181 | $4,229 |
2019
| Short return visit (20+ min) | 74 | $2,711 |
2018
| Short return visit (20+ min) | 30 | $1,332 |
Drugs they prescribed that Part D paid
$3,442,773
Pharmacies billed $3,442,773 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
713 generic and 268 brand-name prescriptions · $3,442,773 in drug cost · 28 antibiotic prescriptions to 11 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Pomalyst | 35 | $755,625 | $21,589 |
| Revlimid | 40 | $754,591 | $18,865 |
| Jakafi | 14 | $244,045 | $17,432 |
| Sprycel | 12 | $208,429 | $17,369 |
| Xtandi | 12 | $172,173 | $14,348 |
See all 26 drugs
| Pomalyst | 35 | $755,625 | $21,589 |
| Revlimid | 40 | $754,591 | $18,865 |
| Jakafi | 14 | $244,045 | $17,432 |
| Sprycel | 12 | $208,429 | $17,369 |
| Xtandi | 12 | $172,173 | $14,348 |
| Tavalisse | 11 | $164,033 | $14,912 |
| Kisqali | 12 | $136,249 | $11,354 |
| Venclexta | 27 | $110,790 | $4,103 |
| Eliquis | 49 | $31,989 | $653 |
| Exemestane | 35 | $2,629 | $75 |
| Letrozole | 105 | $2,387 | $23 |
| Hydroxyurea | 72 | $2,091 | $29 |
| Tamoxifen Citrate | 63 | $1,306 | $21 |
| Acyclovir | 48 | $1,111 | $23 |
| Dexamethasone | 42 | $815 | $19 |
| Potassium Chloride | 28 | $458 | $16 |
| Gabapentin | 27 | $413 | $15 |
| Anastrozole | 18 | $341 | $19 |
| Prochlorperazine Maleate | 31 | $326 | $11 |
| Sulfamethoxazole-Trimethoprim | 21 | $274 | $13 |
| Ondansetron | 30 | $261 | $9 |
| Ondansetron Odt | 11 | $126 | $11 |
| Prednisone | 13 | $115 | $9 |
| Lorazepam | 23 | $115 | $5 |
| Venlafaxine Hcl Er | 21 | $107 | $5 |
| Amlodipine Besylate | 15 | $103 | $7 |
Year by year
| 2024 | 981 | 166 | None | 27% | $3,442,773 |
| 2023 | 903 | 152 | None | None | $2,568,981 |
| 2022 | 1,018 | 167 | 2% (16) | None | $3,126,064 |
| 2021 | 1,023 | 163 | 2% (18) | 27% | $2,548,336 |
| 2020 | 1,017 | 150 | 5% (48) | 20% | $1,641,133 |
| 2019 | 928 | 152 | 3% (26) | None | $1,355,467 |
| 2018 | 955 | 123 | 3% (26) | 24% | $1,806,520 |
| 2017 | 961 | 122 | 5% (51) | 19% | $1,155,371 |
| 2016 | 644 | 111 | 9% (60) | 21% | $902,458 |
| 2015 | 56 | 25 | 23% (13) | None | $35,752 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 23 drugs
| Revlimid | 32 | $575,687 | $17,990 |
| Pomalyst | 13 | $369,528 | $28,425 |
| Lenalidomide | 25 | $349,001 | $13,960 |
| Vonjo | 15 | $345,947 | $23,063 |
| Jakafi | 13 | $237,231 | $18,249 |
| Venclexta | 15 | $64,777 | $4,318 |
| Eliquis | 63 | $42,603 | $676 |
| Exemestane | 46 | $9,266 | $201 |
| Letrozole | 101 | $2,962 | $29 |
| Hydroxyurea | 79 | $2,510 | $32 |
| Tamoxifen Citrate | 62 | $1,895 | $31 |
| Acyclovir | 38 | $1,099 | $29 |
| Venlafaxine Hcl Er | 24 | $977 | $41 |
| Gabapentin | 42 | $714 | $17 |
| Potassium Chloride | 21 | $417 | $20 |
| Anastrozole | 22 | $330 | $15 |
| Ondansetron | 22 | $283 | $13 |
| Dexamethasone | 16 | $228 | $14 |
| Sulfamethoxazole-Trimethoprim | 16 | $190 | $12 |
| Sertraline | 11 | $154 | $14 |
| Lorazepam | 19 | $142 | $7 |
| Lisinopril | 13 | $55 | $4 |
| Alendronate | 12 | $23 | $2 |
2022: 22 drugs
| Revlimid | 67 | $1,273,969 | $19,014 |
| Jakafi | 28 | $485,827 | $17,351 |
| Vonjo | 18 | $385,265 | $21,404 |
| Pomalyst | 13 | $332,975 | $25,613 |
| Eliquis | 80 | $49,756 | $622 |
| Venclexta | 12 | $27,996 | $2,333 |
| Exemestane | 44 | $8,599 | $195 |
| Letrozole | 122 | $3,675 | $30 |
| Hydroxyurea | 73 | $3,168 | $43 |
| Tamoxifen Citrate | 71 | $2,043 | $29 |
| Ondansetron | 32 | $1,125 | $35 |
| Dexamethasone | 35 | $785 | $22 |
| Acyclovir | 29 | $706 | $24 |
| Venlafaxine Hcl Er | 33 | $659 | $20 |
| Gabapentin | 32 | $618 | $19 |
| Anastrozole | 12 | $295 | $25 |
| Potassium Chloride | 30 | $290 | $10 |
| Prochlorperazine Maleate | 27 | $266 | $10 |
| Lorazepam | 39 | $162 | $4 |
| Zolpidem | 16 | $111 | $7 |
| Sulfamethoxazole-Trimethoprim | 14 | $88 | $6 |
| Citalopram Hbr | 11 | $23 | $2 |
2021: 22 drugs
| Revlimid | 51 | $897,759 | $17,603 |
| Jakafi | 49 | $712,622 | $14,543 |
| Pomalyst | 11 | $233,340 | $21,213 |
| Tavalisse | 13 | $157,834 | $12,141 |
| Eliquis | 81 | $54,776 | $676 |
| Venclexta | 12 | $27,560 | $2,297 |
| Exemestane | 29 | $10,129 | $349 |
| Letrozole | 132 | $5,785 | $44 |
| Hydroxyurea | 74 | $3,991 | $54 |
| Tamoxifen Citrate | 88 | $3,538 | $40 |
| Venlafaxine Hcl Er | 32 | $1,060 | $33 |
| Dexamethasone | 28 | $677 | $24 |
| Acyclovir | 37 | $633 | $17 |
| Gabapentin | 41 | $619 | $15 |
| Potassium Chloride | 38 | $584 | $15 |
| Anastrozole | 11 | $325 | $30 |
| Prochlorperazine Maleate | 21 | $319 | $15 |
| Ondansetron Odt | 11 | $276 | $25 |
| Ondansetron | 16 | $264 | $16 |
| Zolpidem | 15 | $196 | $13 |
| Lorazepam | 37 | $192 | $5 |
| Sulfamethoxazole-Trimethoprim | 13 | $39 | $3 |
2020: 24 drugs
| Revlimid | 46 | $777,425 | $16,901 |
| Jakafi | 16 | $237,235 | $14,827 |
| Tavalisse | 11 | $125,938 | $11,449 |
| Eliquis | 65 | $37,487 | $577 |
| Hydroxyurea | 72 | $5,004 | $69 |
| Letrozole | 160 | $4,937 | $31 |
| Tamoxifen Citrate | 94 | $4,514 | $48 |
| Venlafaxine Hcl Er | 44 | $1,327 | $30 |
| Potassium Chloride | 13 | $1,132 | $87 |
| Dexamethasone | 41 | $1,060 | $26 |
| Gabapentin | 34 | $581 | $17 |
| Anastrozole | 22 | $560 | $25 |
| Diphenoxylate-Atropine | 14 | $458 | $33 |
| Hydrocodone-Acetaminophen | 19 | $416 | $22 |
| Acyclovir | 23 | $311 | $14 |
| Duloxetine | 12 | $274 | $23 |
| Prochlorperazine Maleate | 19 | $271 | $14 |
| Methadone | 17 | $239 | $14 |
| Ondansetron | 12 | $238 | $20 |
| Ondansetron Odt | 16 | $216 | $14 |
| Lorazepam | 28 | $134 | $5 |
| Zolpidem | 13 | $132 | $10 |
| Prednisone | 13 | $127 | $10 |
| Citalopram Hbr | 11 | $12 | $1 |
2019: 16 drugs
| Revlimid | 26 | $406,635 | $15,640 |
| Iclusig | 18 | $321,982 | $17,888 |
| Sprycel | 13 | $189,554 | $14,581 |
| Eliquis | 55 | $30,867 | $561 |
| Exemestane | 21 | $7,605 | $362 |
| Hydroxyurea | 91 | $6,103 | $67 |
| Tamoxifen Citrate | 111 | $5,357 | $48 |
| Letrozole | 157 | $3,675 | $23 |
| Venlafaxine Hcl Er | 56 | $1,243 | $22 |
| Dexamethasone | 24 | $817 | $34 |
| Acyclovir | 14 | $385 | $28 |
| Hydrocodone-Acetaminophen | 11 | $384 | $35 |
| Prochlorperazine Maleate | 23 | $262 | $11 |
| Lorazepam | 40 | $182 | $5 |
| Gabapentin | 12 | $163 | $14 |
| Furosemide | 11 | $51 | $5 |
2018: 23 drugs
| Revlimid | 58 | $868,830 | $14,980 |
| Iclusig | 12 | $213,495 | $17,791 |
| Ibrance | 17 | $192,188 | $11,305 |
| Sprycel | 12 | $158,929 | $13,244 |
| Imbruvica | 19 | $143,518 | $7,554 |
| Imatinib Mesylate | 23 | $100,617 | $4,375 |
| Procrit | 18 | $55,312 | $3,073 |
| Eliquis | 46 | $24,645 | $536 |
| Xarelto | 12 | $8,265 | $689 |
| Exemestane | 20 | $6,667 | $333 |
| Hydroxyurea | 105 | $5,625 | $54 |
| Tamoxifen Citrate | 95 | $3,457 | $36 |
| Letrozole | 127 | $2,714 | $21 |
| Dexamethasone | 29 | $453 | $16 |
| Gabapentin | 21 | $358 | $17 |
| Venlafaxine Hcl Er | 12 | $312 | $26 |
| Ondansetron Odt | 12 | $212 | $18 |
| Calcitriol | 11 | $177 | $16 |
| Prednisone | 25 | $162 | $6 |
| Lorazepam | 37 | $154 | $4 |
| Acyclovir | 15 | $132 | $9 |
| Pantoprazole | 12 | $109 | $9 |
| Prochlorperazine Maleate | 14 | $58 | $4 |
2017: 24 drugs
| Revlimid | 26 | $330,859 | $12,725 |
| Sprycel | 14 | $172,703 | $12,336 |
| Imbruvica | 13 | $98,655 | $7,589 |
| Imatinib Mesylate | 12 | $90,970 | $7,581 |
| Procrit | 24 | $71,073 | $2,961 |
| Eliquis | 35 | $13,350 | $381 |
| Exemestane | 21 | $9,693 | $462 |
| Hydroxyurea | 88 | $5,723 | $65 |
| Letrozole | 141 | $2,615 | $19 |
| Tamoxifen Citrate | 65 | $1,532 | $24 |
| Valacyclovir | 16 | $405 | $25 |
| Anastrozole | 18 | $330 | $18 |
| Calcitriol | 11 | $312 | $28 |
| Allopurinol | 14 | $305 | $22 |
| Gabapentin | 30 | $305 | $10 |
| Dexamethasone | 15 | $223 | $15 |
| Sulfamethoxazole-Trimethoprim | 12 | $223 | $19 |
| Venlafaxine | 20 | $210 | $11 |
| Prednisone | 22 | $198 | $9 |
| Lorazepam | 44 | $168 | $4 |
| Ondansetron | 15 | $163 | $11 |
| Escitalopram | 11 | $139 | $13 |
| Prochlorperazine Maleate | 27 | $128 | $5 |
| Alendronate | 17 | $67 | $4 |
2016: 23 drugs
| Revlimid | 19 | $210,305 | $11,069 |
| Sprycel | 11 | $124,337 | $11,303 |
| Imatinib Mesylate | 11 | $105,019 | $9,547 |
| Imbruvica | 11 | $103,124 | $9,375 |
| Procrit | 24 | $69,372 | $2,891 |
| Oxycontin | 11 | $4,822 | $438 |
| Hydroxyurea | 53 | $1,974 | $37 |
| Letrozole | 62 | $1,399 | $23 |
| Tamoxifen Citrate | 28 | $911 | $33 |
| Valacyclovir | 14 | $533 | $38 |
| Hydrocodone-Acetaminophen | 11 | $363 | $33 |
| Zolpidem | 14 | $350 | $25 |
| Anastrozole | 13 | $264 | $20 |
| Gabapentin | 14 | $239 | $17 |
| Calcitriol | 11 | $223 | $20 |
| Prochlorperazine Maleate | 15 | $208 | $14 |
| Dexamethasone | 15 | $187 | $12 |
| Ondansetron | 11 | $186 | $17 |
| Sulfamethoxazole-Trimethoprim | 11 | $150 | $14 |
| Warfarin | 20 | $138 | $7 |
| Levofloxacin | 11 | $130 | $12 |
| Prednisone | 15 | $122 | $8 |
| Lorazepam | 13 | $69 | $5 |
Money from drug and device companies
$115 in 2025
| 2025 | 4 | 7 | None | $115 |
| 2024 | 3 | 5 | None | $98 |
| 2023 | 2 | 2 | None | $43 |
| 2021 | 2 | 4 | None | $66 |
| 2020 | 1 | 2 | None | $25 |
| 2019 | 2 | 2 | None | $29 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Celgene | Reblozyl | $69 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | None | $16 | 1 payment
|
| Abbvie | Imbruvica | $16 | 1 payment
|
| Tempus AI | Xt Cdx | $14 | 1 payment
|
See all 7 published payments
| Abbvie | Meals · 2025-12-03 | Imbruvica | $16 |
| Tempus AI | Meals · 2025-10-29 | Xt Cdx | $14 |
| Celgene | Meals · 2025-08-19 | Reblozyl | $18 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-06-20 | None | $16 |
| Celgene | Meals · 2025-05-12 | Reblozyl | $19 |
| Celgene | Meals · 2025-03-19 | Reblozyl | $16 |
| Celgene | Meals · 2025-03-04 | Reblozyl | $17 |
See earlier years (2024, 2023, 2021, 2020, 2019)
2024: $98
| Celgene | Reblozyl | $52 | 3 payments
|
| Medtronic | Osteocool Rf Ablation System | $35 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $11 | 1 payment
|
2023: $43
| Pfizer | Ibrance | $25 | 1 payment
|
| Celgene | Reblozyl | $18 | 1 payment
|
2021: $66
| Pfizer | Inlyta | $54 | 3 payments
|
| Gilead Sciences | None | $12 | 1 payment
|
2020: $25
| Pfizer | Xalkori | $25 | 2 payments
|
2019: $29
| Boston Scientific | Watchman | $16 | 1 payment
|
| Pfizer | Braftovi | $13 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Merck Sharp & Dohme LLC · A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With Or Without Bevacizumab for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer Keynote-B96 , Engot-Ov65 · 2023 | Their institution | $296,483 |
| Merck Sharp & Dohme LLC · A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With Or Without Bevacizumab for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer Keynote-B96 , Engot-Ov65 · 2022 | Their institution | $46,041 |
| E.R. Squibb & Sons, L.L.C. · Phase III Study - Breast Cancer Hr Pos Her2 Neg Neo Adjuvant · 2022 | Their institution | $43,812 |
| Merck Sharp & Dohme LLC · A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With Or Without Bevacizumab for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer Keynote-B96 , Engot-Ov65 · 2024 | Their institution | $37,217 |
| TOLMAR, INC. · Tol2506a · 2023 | Their institution | $35,184 |
| E.R. Squibb & Sons, L.L.C. · Phase III Study - Breast Cancer Hr Pos Her2 Neg Neo Adjuvant · 2021 | Their institution | $34,525 |
| E.R. Squibb & Sons, L.L.C. · Phase III Study - Breast Cancer Hr Pos Her2 Neg Neo Adjuvant · 2020 | Their institution | $33,130 |
| Eli Lilly and Company · Ember-3: A Randomized, Open-Label, Phase 3 Study of Ly3484356 Vs Investigator'S Choice of Endocrine Therapy, in Patients With Estrogen Receptor Positive, Her2 Negative Locally Advanced Or Metastatic Breast Cancer Previously Treated With Endocrine Therapy · 2025 | Their institution | $30,949 |
| AstraZeneca UK Limited · Cambria-1 A Phase III, Open-Label,Randomised Study To Assess the Efficacy and Safety of Extended Therapy With Camizestrant (Azd9833, A Next Generation, Oral Selective Estrogen Receptor Degrader) Vs Standard Endocrine Therapy (Aromatase Inhibitor Or Tamoxifen) in Patients With Er+/Her2 · 2024 | Their institution | $20,937 |
| Tolmar, Inc. · Open-Label, Safety Extension Study for Subjects With Hormone-Receptor-Positive (Hr+), Human Epidermal Growth Factor Receptor 2 (Her2)-Negative Breast Cancer Who Have Completed the Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (Ovelia) Study · 2024 | Their institution | $20,192 |
| AstraZeneca UK Limited · Cambria-1 A Phase III, Open-Label,Randomised Study To Assess the Efficacy and Safety of Extended Therapy With Camizestrant (Azd9833, A Next Generation, Oral Selective Estrogen Receptor Degrader) Vs Standard Endocrine Therapy (Aromatase Inhibitor Or Tamoxifen) in Patients With Er+/Her2 · 2025 | Their institution | $20,060 |
| Novartis Pharmaceuticals Corporation · Epik-B2: A Two Part, Phase III, Multicenter, Randomized (1:1), Double-Blind, Placebo-Controlled Study To Assess the Efficacy and Safety of Alpelisib (Byl719) in Combination With Trastuzumab and Pertuzumab As Maintenance Therapy in Patients With Her2-Positive Advanced Breast Cancer With A Pik3ca Mutation · 2023 | Their institution | $18,160 |
| Genentech, Inc. · Phase III Study To Compare Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Mbc · 2025 | Their institution | $17,500 |
| Genentech, Inc. · Giredestrant Cdki of Choice in Esr1m Enriched 1l Hr Mbc Secondary Endocrine Resistant Patients · 2024 | Their institution | $16,500 |
| TOLMAR, INC. · Tol2506a · 2022 | Their institution | $13,500 |
| Tolmar, Inc. · A Phase 3, Single Arm, Openlabel Study Evaluating Ovarian Suppression Following Threemonth Leuprolide Acetate for Injectable Suspension (Tol2506) in Combination With Endocrine Therapy in Premenopausal Subjects With Hormonereceptor Positive (Hr+), Human Epidermal Growth Factor Receptor 2 (Her2)Negative Breast Cancer · 2024 | Their institution | $13,416 |
| Merck Sharp & Dohme LLC · A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With Or Without Bevacizumab for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer Keynote-B96 , Engot-Ov65 · 2025 | Their institution | $9,801 |
| Genentech, Inc. · Chemo Trastuzumab Vs Chemo Trastuzumab Pertuzumab · 2023 | Their institution | $9,271 |
| TOLMAR, INC. · Tol2506a-Ext · 2025 | Their institution | $8,973 |
| E.R. Squibb & Sons, L.L.C. · Phase III Study - Breast Cancer Hr Pos / Her2 Neg Neo Adjuvant · 2023 | Their institution | $6,800 |
| Tolmar, Inc. · A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate for Injectable Suspension (Tol2506) in Combination With Endocrine Therapy in Premenopausal Subjects With Hormone-Receptor–Positive (Hr+), Human Epidermal Growth Factor Receptor 2 (Her2)-Negative Breast Cancer · 2024 | Their institution | $5,784 |
| Becton, Dickinson and Company · 2022 | Their institution | $4,385 |
| TOLMAR, INC. · Tol2506a · 2025 | Their institution | $4,044 |
| Novartis Pharmaceuticals Corporation · Clinical Trial To Assess the Efficacy and Safety of An Alternative Dosing Regimen of Ribociclib in Breast Cancer · 2025 | Their institution | $3,500 |
| E.R. Squibb & Sons, L.L.C. · Phase III Study - Breast Cancer Hr Pos / Her2 Neg Neo Adjuvant · 2024 | Their institution | $3,390 |
| Eli Lilly and Company · Chemotherapy Induced Peripheral Neuropathy Natural History Study (Epiphany) · 2022 | Their institution | $1,779 |
| Eli Lilly and Company · Ember-3: A Randomized, Open-Label, Phase 3 Study of Ly3484356 Vs Investigator'S Choice of Endocrine Therapy, in Patients With Estrogen Receptor Positive, Her2 Negative Locally Advanced Or Metastatic Breast Cancer Previously Treated With Endocrine Therapy · 2022 | Their institution | $1,361 |
| Janssen Research & Development, LLC · A Prospective Multinational Study of Real Life Current Standards of Care in Patients With Relapsed and/Or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Pi Imid and Cd38 Monoclonal Antibody Treatment · 2023 | Their institution | $1,300 |
| Eli Lilly and Company · Ember-3: A Randomized Open-Label Phase 3 Study of Ly3484356 Vs Investigator'S Choice of Endocrine Therapy in Patients With Estrogen Receptor Positive Her2 Negative Locally Advanced Or Metastatic Breast Cancer Previously Treated With Endocrine Therapy · 2023 | Their institution | $1,222 |
| Genentech, Inc. · Chemo Trastuzumab Vs Chemo Trastuzumab Pertuzumab · 2025 | Their institution | $673 |
| Genentech, Inc. · Chemo Trastuzumab Vs Chemo Trastuzumab Pertuzumab · 2022 | Their institution | $673 |
| Eli Lilly and Company · Ember-3: A Randomized, Open-Label, Phase 3 Study of Ly3484356 Vs Investigator'S Choice of Endocrine Therapy, in Patients With Estrogen Receptor Positive, Her2 Negative Locally Advanced Or Metastatic Breast Cancer Previously Treated With Endocrine Therapy · 2024 | Their institution | $81 |
| Genentech, Inc. · Chemo Trastuzumab Vs Chemo Trastuzumab Pertuzumab · 2024 | Their institution | $55 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 0.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1962732354
- Trained
- University of Minnesota Medical School, 2009 · 17 years ago
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Student in a training program (390200000X)
- Mailing address
- 3350 La Jolla Village Dr, San Diego, CA, 92161
- NPI first listed
- 2010-01-06
- NPI last updated
- 2010-01-06
This is when the NPI record was last certified, not a medical board exam.